DE60036105D1 - Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs - Google Patents

Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs

Info

Publication number
DE60036105D1
DE60036105D1 DE60036105T DE60036105T DE60036105D1 DE 60036105 D1 DE60036105 D1 DE 60036105D1 DE 60036105 T DE60036105 T DE 60036105T DE 60036105 T DE60036105 T DE 60036105T DE 60036105 D1 DE60036105 D1 DE 60036105D1
Authority
DE
Germany
Prior art keywords
cancer
interleukin
treatment
simplex virus
herpes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036105T
Other languages
English (en)
Inventor
Richard J Whitley
James Macdowell Markert
George Yancey Gillespie
Jacqueline Ness Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26835933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60036105(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of DE60036105D1 publication Critical patent/DE60036105D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60036105T 1999-06-08 2000-06-08 Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs Expired - Lifetime DE60036105D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13817399P 1999-06-08 1999-06-08
US14431499P 1999-07-16 1999-07-16
PCT/US2000/040165 WO2000075292A1 (en) 1999-06-08 2000-06-08 Herpes simplex virus expressing foreign genes and method for treating cancers therewith

Publications (1)

Publication Number Publication Date
DE60036105D1 true DE60036105D1 (de) 2007-10-04

Family

ID=26835933

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036105T Expired - Lifetime DE60036105D1 (de) 1999-06-08 2000-06-08 Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs

Country Status (7)

Country Link
EP (1) EP1190040B1 (de)
JP (1) JP2003501445A (de)
AT (1) ATE371031T1 (de)
AU (1) AU6120600A (de)
CA (1) CA2376939A1 (de)
DE (1) DE60036105D1 (de)
WO (1) WO2000075292A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
CA2563103C (en) * 2004-03-31 2015-02-17 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
TWI688395B (zh) 2010-03-23 2020-03-21 英翠克頌公司 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
HUE041799T2 (hu) 2011-09-08 2019-05-28 Univ New York Onkolitikus Herpes simplex vírus és terápiás alkalmazásai
ES2671728T3 (es) * 2011-10-11 2018-06-08 Universität Zürich Prorektorat Mnw Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
KR102081567B1 (ko) 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
ES2873093T3 (es) 2015-03-26 2021-11-03 Oncosec Medical Inc Método para el tratamiento de neoplasias malignas
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017106795A1 (en) * 2015-12-18 2017-06-22 Oncosec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
WO2018026872A1 (en) * 2016-08-01 2018-02-08 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5750346A (en) * 1995-08-07 1998-05-12 The Perkin-Elmer Corporation Host organism capture
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy

Also Published As

Publication number Publication date
EP1190040B1 (de) 2007-08-22
CA2376939A1 (en) 2000-12-14
JP2003501445A (ja) 2003-01-14
AU6120600A (en) 2000-12-28
EP1190040A1 (de) 2002-03-27
EP1190040A4 (de) 2003-01-02
WO2000075292A1 (en) 2000-12-14
ATE371031T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE285239T1 (de) Dna enthaltende impfstoffen
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP0689586A4 (de) Funktion und aktivität des viralen proteins r (vpr)
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO1999047152A3 (en) Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
AU2002228940A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
HUP9701093A1 (hu) Huminsavtartalmú gyógyászati készítmény
YU5002A (sh) Jedinjenja i postupci za lečenje i dijagnozu raka pluća
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
CA2347371A1 (en) HEMATOPOIETIC REGULATION FACTORS AND METHODS OF USE
DE69432517T2 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof

Legal Events

Date Code Title Description
8332 No legal effect for de